| Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above (NCT05404945) | University of Virginia | 2022-07-26 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT05362773) | MacroGenics | 2022-07-13 |
| Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma (NCT06822855) | Azienda USL Reggio Emilia - IRCCS | 2022-06-23 |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma (NCT04510636) | University Health Network, Toronto | 2021-12-20 |
| Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) (NCT05008224) | Merck Sharp & Dohme LLC | 2021-10-07 |
| PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL (NCT04624984) | Sun Yat-sen University | 2021-04-01 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients (NCT04858568) | University Hospital Southampton NHS Foundation Trust | 2021-03-11 |
| Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (NCT04486391) | BeiGene | 2020-12-14 |
| Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas (NCT04288726) | Baylor College of Medicine | 2020-09-16 |
| Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT04318080) | BeiGene | 2020-08-20 |
| Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT04342936) | Jiangsu HengRui Medicine Co., Ltd. | 2020-07-17 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer (NCT04254107) | Seagen Inc. | 2020-05-29 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis (NCT04187872) | University of Florida | 2020-01-10 |
| Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy (NCT03480334) | University of Cologne | 2019-12-05 |
| Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma (NCT03652441) | University of Cologne | 2019-11-13 |
| Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma (NCT04067037) | Henan Cancer Hospital | 2019-08-26 |
| Itacitinib + Everolimus in Hodgkin Lymphoma (NCT03697408) | University of Pennsylvania | 2019-02-11 |
| Interim PET/CT-adapted Use of PD-1 Inhibitor Combined With De-escalated Chemotherapy-AVD in Classic Hodgkin Lymphoma (NCT07720011) | Peking University People's Hospital | 2019-02-01 |
| Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma (NCT03331341) | University of Washington | 2019-01-09 |
| Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT03739619) | Emory University | 2018-11-26 |
| Phase Ib of L-NMMA and Pembrolizumab (NCT03236935) | The Methodist Hospital Research Institute | 2018-08-27 |
| An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma (NCT03580564) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2018-08-01 |
| Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL (NCT03471351) | Rhizen Pharmaceuticals SA | 2018-07-18 |
| Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas (NCT03205891) | M.D. Anderson Cancer Center | 2018-03-01 |
| OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy (NCT03527628) | King Abdullah International Medical Research Center | 2018-01-01 |
| B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes (NCT03327571) | Takeda | 2017-11-21 |
| PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma (NCT03226249) | Northwestern University | 2017-11-09 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (NCT03212404) | Checkpoint Therapeutics, Inc. | 2017-09-20 |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers (NCT03190174) | Sarcoma Oncology Research Center, LLC | 2017-08-24 |
| A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma (NCT03209973) | BeiGene | 2017-04-21 |
| Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation (NCT02981914) | University of Chicago | 2017-03-07 |
| Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma (NCT03004833) | University of Cologne | 2017-02-21 |
| Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma (NCT03042247) | Marco Picardi | 2017-01-24 |
| Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT02940301) | Ohio State University Comprehensive Cancer Center | 2016-12-20 |
| HD21 for Advanced Stages (NCT02661503) | University of Cologne | 2016-07-01 |
| Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT02824029) | Barbara Ann Karmanos Cancer Institute | 2016-06-01 |
| Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma (NCT02815137) | Centre Henri Becquerel | 2016-06-01 |
| Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma (NCT02808520) | Martin-Luther-Universität Halle-Wittenberg | 2016-03-01 |
| Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents (NCT02684708) | University of Giessen | 2015-10-01 |
| Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin (NCT02414568) | The Lymphoma Academic Research Organisation | 2015-07-17 |
| A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) (NCT02332668) | Merck Sharp & Dohme LLC | 2015-03-19 |
| Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma (NCT02243436) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2014-11-11 |
| Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma (NCT00305149) | Rambam Health Care Campus | 1999-07-01 |